Keymen İlaç
Keymen İlaç, a subsidiary of Alagöz Holding, has been a leading provider of vaccines and pharmaceuticals in Turkey since 1973. The company played a pioneering role in the fight against COVID-19 by introducing Sinovac to Turkey and conducting phase 3 clinical trials. With over 48 years of experience in the pharmaceutical sector and collaborations with institutions like TÜBİTAK and Iğdır University, Keymen İlaç continues to serve both Turkey and the world from Ankara, focusing on community health and innovative solutions.
Industries
Nr. of Employees
medium (51-250)
Keymen İlaç
Mustafa Kemal Mah. Alagöz Sk. No:8 - 06530, Çankaya, ANKARA
Products
Recombinant Hepatitis B vaccine — adult formulation (20 mcg/1 ml)
Recombinant hepatitis B surface antigen in an injectable suspension for single-dose administration.
Recombinant Hepatitis B vaccine — pediatric formulation (10 mcg/0.5 ml)
Recombinant hepatitis B surface antigen in an injectable suspension for pediatric dosing.
Live attenuated measles vaccine (lyophilized)
Live attenuated measles virus provided as a lyophilized powder with solvent for injection.
Diphtheria–Tetanus adult vaccine (adsorbed)
Adsorbed toxoid vaccine for diphtheria and tetanus in an injectable suspension.
BCG vaccine (live attenuated, lyophilized)
Lyophilized Bacillus Calmette–Guérin vaccine supplied with solvent for multi-dose presentation.
Measles–Mumps–Rubella (MMR) live attenuated vaccine
Combined live attenuated vaccine for measles, mumps and rubella in lyophilized form.
Recombinant Hepatitis B vaccine — adult formulation (20 mcg/1 ml)
Recombinant hepatitis B surface antigen in an injectable suspension for single-dose administration.
Recombinant Hepatitis B vaccine — pediatric formulation (10 mcg/0.5 ml)
Recombinant hepatitis B surface antigen in an injectable suspension for pediatric dosing.
Live attenuated measles vaccine (lyophilized)
Live attenuated measles virus provided as a lyophilized powder with solvent for injection.
Diphtheria–Tetanus adult vaccine (adsorbed)
Adsorbed toxoid vaccine for diphtheria and tetanus in an injectable suspension.
BCG vaccine (live attenuated, lyophilized)
Lyophilized Bacillus Calmette–Guérin vaccine supplied with solvent for multi-dose presentation.
Measles–Mumps–Rubella (MMR) live attenuated vaccine
Combined live attenuated vaccine for measles, mumps and rubella in lyophilized form.
Services
Importation, storage and distribution of vaccine doses to public-health programs and healthcare providers.
Support for late-stage clinical trials for vaccines, including execution of Phase 3 studies.
Management of post-approval commercialization, marketing and distribution of licensed vaccines and pharmaceuticals.
Joint development projects with universities and national research agencies for drug and diagnostic kit production.
Sourcing and provision of analytical laboratory equipment and related services.
Provision of official channels and contact points for adverse event and safety reporting for marketed products.
Importation, storage and distribution of vaccine doses to public-health programs and healthcare providers.
Support for late-stage clinical trials for vaccines, including execution of Phase 3 studies.
Management of post-approval commercialization, marketing and distribution of licensed vaccines and pharmaceuticals.
Joint development projects with universities and national research agencies for drug and diagnostic kit production.
Sourcing and provision of analytical laboratory equipment and related services.
Provision of official channels and contact points for adverse event and safety reporting for marketed products.
Expertise Areas
- Vaccine supply and distribution
- Clinical trial management (Phase 3)
- Pharmacovigilance and adverse-event reporting
- Regulatory compliance and product registration
Key Technologies
- Live attenuated vaccine formulations
- Inactivated vaccine formulations
- Recombinant protein vaccine technology
- Recombinant monoclonal antibody therapeutics
News & Updates
First to bring Sinovac vaccine to Turkey during COVID-19 pandemic
Keymen İlaç introduced Sinovac vaccine to Turkey, marking a sector first.
Conducted phase 3 clinical trials for COVID-19 vaccine
Keymen İlaç carried out phase 3 clinical trials for COVID-19 vaccines.
Over 48 years of experience in the pharmaceutical sector
Keymen İlaç has a long-standing history of serving community health in Turkey.
First to bring Sinovac vaccine to Turkey during COVID-19 pandemic
Keymen İlaç introduced Sinovac vaccine to Turkey, marking a sector first.
Conducted phase 3 clinical trials for COVID-19 vaccine
Keymen İlaç carried out phase 3 clinical trials for COVID-19 vaccines.
Over 48 years of experience in the pharmaceutical sector
Keymen İlaç has a long-standing history of serving community health in Turkey.